A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

BACKGROUND: Tuberculosis (TB) remains the leading cause of infectious disease-related death. Recently, a trial of BCG revaccination and vaccination with H4:IC31, a recombinant protein vaccine, in South African adolescents (Aeras C-040-404) showed efficacy in preventing sustained QuantiFERON (QFT) co...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Bekker, Linda-Gail, Dintwe, One, Fiore-Gartland, Andrew, Middelkoop, Keren, Hutter, Julia, Williams, Anthony, Randhawa, April K., Ruhwald, Morten, Kromann, Ingrid, Andersen, Peter L., DiazGranados, Carlos A., Rutkowski, Kathryn T., Tait, Dereck, Miner, Maurine D., Andersen-Nissen, Erica, De Rosa, Stephen C., Seaton, Kelly E., Tomaras, Georgia D., McElrath, M. Juliana, Ginsberg, Ann, Kublin, James G.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201034/
https://ncbi.nlm.nih.gov/pubmed/32382714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100313
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars